1.中国中医科学院中医基础理论研究所,北京市东城区东直门内南小街16号,100700
2.南京中医药大学第三临床医学院
3.陕西中医药大学
gcp306@126.com
收稿:2021-12-20,
修回:2022-05-27,
纸质出版:2022-09-02
移动端阅览
吴珊,王传池,林明欣等.近30年中医药治疗冠心病痰瘀互结证用药概况分析[J].中医杂志,2022,63(17):1685-1690.
WU Shan,WANG Chuanchi,LIN Mingxin,et al.Analysis of the Medications in Treating Coronary Heart Disease with Binding of Phlegm and Stasis Syndrome by Traditional Chinese Medicine in Recent 30 Years[J].Journal of Traditional Chinese Medicine,2022,63(17):1685-1690.
吴珊,王传池,林明欣等.近30年中医药治疗冠心病痰瘀互结证用药概况分析[J].中医杂志,2022,63(17):1685-1690. DOI: 10.13288/j.11-2166/r.2022.17.016.
WU Shan,WANG Chuanchi,LIN Mingxin,et al.Analysis of the Medications in Treating Coronary Heart Disease with Binding of Phlegm and Stasis Syndrome by Traditional Chinese Medicine in Recent 30 Years[J].Journal of Traditional Chinese Medicine,2022,63(17):1685-1690. DOI: 10.13288/j.11-2166/r.2022.17.016.
目的
2
分析近30年中医药治疗冠心病痰瘀互结证用药概况,为中医药治疗冠心病痰瘀互结证提供参考。
方法
2
计算机检索1991年1月1日至2021年9月1日中国知识资源总库、中文科技期刊数据库、中国学术期刊数据库、PubMed收录的中医药治疗冠心病痰瘀互结证相关研究文献,根据美国国家临床指南交换所(NGC)的证据等级对纳入文献进行证据分级。提取冠心病痰瘀互结证随机对照试验研究(A级证据)中的常用传统方剂、自拟方剂及中成药药物信息,并分析不同等级文献单味中药使用情况。
结果
2
共纳入冠心病痰瘀互结证临床治疗用药文献286篇,其中传统方剂79篇(27.62%),自拟方剂165篇(57.69%),中成药42篇(14.69%),累计治疗患者11 276例。文献证据级别评价结果为A级文献196篇(68.53%),B级文献20篇(6.99%),C级文献70篇(24.48%)。A级文献中,瓜蒌薤白半夏汤及血府逐瘀汤为常用的传统方剂,涉及其加减组合的文献共计27篇;冠脉宁通方(5篇)为最常用的自拟方;丹蒌片(17篇)是最常用的中成药。治疗冠心病痰瘀互结证的高频次药物有瓜蒌(67.48%)、丹参(63.29%)、半夏(62.24%)、川芎(47.90%)、薤白(47.90%)、甘草(40.21%)、黄芪(33.57%)、赤芍(30.77%)、红花(30.77%)、郁金(30.07%);其中A级文献涉及高频次药物为瓜蒌(46.15%)、半夏(41.61%)、丹参(41.26%)、川芎(33.22%)、薤白(30.07%);B级文献涉及高频次药物为瓜蒌(5.59%)、半夏(5.59%)、丹参(5.59%)、薤白(5.24%)、川芎(3.50%);C级文献涉及高频次药物为丹参(16.43%)、瓜蒌(15.73%)、半夏(15.03%)、薤白(12.59%)、川芎(11.19%)。
结论
2
中医药治疗冠心病痰瘀互结证常用药物为瓜蒌、丹参、半夏、川芎、薤白、甘草、黄芪、赤芍、红花、郁金等,体现了化痰祛瘀的主要治则,以及对清热解毒、凉血活血、宽胸散结方药的合理运用。
Objective
2
To analyze the medications of traditional Chinese medicine (TCM) in the treatment of coronary heart disease (CHD) with binding of phlegm and stasis syndrome in recent 30 years, thereby providing refe-rence for TCM treatment of CHD with binding of phlegm and stasis syndrome.
Methods
2
The literature on TCM for CHD with binding of phlegm and stasis syndrome was searched from CNKI, VIP, Wanfang and PubMed from January 1st, 1991 to September 1st, 2021 by computer. The included literature was graded according to the National Guideline Clearinghouse (NGC) grade of evidence. The commonly used traditional prescriptions, self-designed prescriptions and Chinese patent medicines in the randomized controlled trials (GRADE A evidence) were extracted, and the use of single herbs in different grades of evidence was analyzed.
Results
2
A total of 286 papers on medications for CHD with binding of phlegm and stasis syndrome were included, involving 79 (27.62%) traditional prescriptions, 165 (57.69%) self-made prescriptions and 42 (14.69%) Chinese patent medicines, and with 11 276 patients. The number of grade A, B and C literature were 196 (68.53%), 20 (6.99%), and 70 (24.48%), respectively. In grade A literature,
Gualou Xiebai Banxia Decoction
(瓜蒌薤白半夏汤),
Xuefu Zhuyu Decoction
(血府逐瘀汤) and their modifications were the most commonly used traditional prescriptions (27 papers);
Guanmai Ningtong Formula
(冠脉宁通方) was the mostly used self-designed prescription (5 papers); and Danlou tablet was the most commonly used Chinese patent medicine (17 papers). The high frequently used single herbs were Gualou (
Fructus Trichosanthis
, 67.48%), Danshen (
Radix et Rhizoma Salviae Miltiorrhizae
, 63.29%), Banxia (
Rhizoma Pinelliae
, 62.24%), Chuanxiong (
Rhizoma Chuanxiong
, 47.90%), Xiebai (
Bulbus Allii Macrostemi
, 47.90%), Gancao (
Radix et Rhizoma Glycyrrhizae
, 40.21%), Huangqi (
Radix Astragali
, 33.57%), Chishao (
Radix Paeoniae Rubra
, 30.77%), Honghua (
Flos Carthami
, 30.77%), and Yujin (
Radix Curcumae
, 30.07%). The single herbs with high frequency in grade A literature were Gualou (46.15%), Banxia (41.61%), Danshen (41.26%), Chuanxiong (33.22%), and Xiebai (30.07%). In grade B literature, the most commonly used single herbs were Gualou (5.59%), Banxia (5.59%), Danshen (5.59%), Xiebai (5.24%) and Chuanxiong (3.50%). The high frequent herbs mentioned in grade C literature were Danshen (16.43%), Gualou (15.73%), Banxia (15.03%), Xiebai (12.59%) and Chuanxiong (11.19%).
Conclusion
2
The commonly used herbs in the treatment of CHD with the binding of phlegm and stasis syndrome are Gualou, Danshen, Banxia, Chuanxiong, Xiebai, Gancao, Huangqi, Chishao, Honghua, and Yujin, following the principle of dissolving phlegm and dispelling stasis, and rationally using prescriptions that have the function of clearing heat and resolving toxins, cooling and invigorating blood, broadening chest and dissipating masses.
卢红蓉 , 杜松 , 胡镜清 . 痰瘀互结证治理论源流考 [J]. 中医杂志 , 2015 , 56 ( 10 ): 811 - 815 .
杜松 , 胡镜清 , 卢红蓉 . 痰瘀互结证现代理论研究进展述评 [J]. 中国中医基础医学杂志 , 2015 , 21 ( 4 ): 477 - 482 .
World Health Organization . Cardiovascular diseases (CVDs) key facts [EB/OL].( 2017-05-17 ) [ 2021-12-25 ]. https://www.who.int/zh/news-room/fact-sheets/detail/cardiovasculardiseases-(cvds) https://www.who.int/zh/news-room/fact-sheets/detail/cardiovasculardiseases-(cvds) .
吴珊 , 王传池 , 张佳乐 , 等 . 近40年痰瘀互结相关研究热点演变与趋势探析 [J]. 中国中医药信息杂志 , 2022 , 29 ( 1 ): 11 - 18 .
王传池 , 许伟明 , 江丽杰 , 等 . 11383例健康人群及冠心病不同阶段患者痰瘀互结证分布规律的多中心横断面研究 [J]. 中医杂志 , 2021 , 62 ( 6 ): 494 - 504 .
苏雪芬 , 李先涛 , 谢蓉 , 等 . 冠心病痰瘀互结证临床用药规律的文献研究 [J]. 中国实验方剂学杂志 , 2015 , 21 ( 14 ): 191 - 198 .
国家药典委员会 . 中华人民共和国药典(2020年版)一部 [M]. 北京 : 中国医药科技出版社 , 2020 .
陈蔚文 . 中药学 [M]. 北京 : 中国中医药出版社 , 2008 .
刘建平 . 循证中医药临床研究方法 [M]. 北京 : 人民卫生出版社 , 2009 : 190 - 191 .
王阶 , 王永炎 , 郭丽丽 . 基于病证结合的中药组方模式研究 [J]. 中国中药杂志 , 2009 , 34 ( 1 ): 2 - 5 .
谭雨晴 , 李军 , 陈恒文 . 基于网络药理学研究瓜蒌薤白半夏汤治疗冠心病的作用机制 [J]. 世界科学技术-中医药现代化 , 2020 , 22 ( 11 ): 3861 - 3871 .
谭达全 , 邓冰湘 , 周祖贻 , 等 . 血府逐瘀汤对大鼠心肌缺血的保护作用 [J]. 湖南中医杂志[ J]. 2005 , 21 ( 4 ): 78 - 79 .
沃兴德 , 丁志山 , 康文英 , 等 . 血府逐瘀汤对缺血再灌注损伤大鼠心肌细胞的保护作用研究 [J]. 浙江中医学院学报 , 2003 , 27 ( 1 ): 50 - 52 .
徐凤芹 , 史大卓 , 陈可冀 , 等 . 精制血府胶囊对犬急性心肌缺血心脏血流动力学和心肌耗氧量的影响 [J]. 中国中西医结合杂志 , 1998 , 18 ( 1 ): 32 - 34 .
王伟 , 马晓昌 , 汪晓芳 , 等 . 精制血府胶囊治疗冠心病心绞痛30例临床观察 [J]. 中医杂志 , 2000 , 40 ( 8 ): 471 - 473,478 .
《中成药治疗优势病种临床应用指南》标准化项目组 . 中成药治疗冠心病临床应用指南(2020年) [J]. 中国中西医结合杂志 , 2021 , 41 ( 4 ): 391 - 417 .
王传池 , 杨燕 , 吴珊 , 等 . 冠心病不同发展阶段中医证演变规律研究 [J]. 中华中医药杂志 , 2019 , 34 ( 5 ): 2101 - 2106 .
李子赟 , 胡镜清 , 王传池 , 等 . 冠心病“热化”病机辨治探微 [J]. 世界科学技术-中医药现代化 , 2019 , 21 ( 10 ): 2009 - 2012 .
胡镜清 . 病机兼化理论框架下的冠心病病机解析 [J]. 中国中医基础医学杂志 , 2017 , 23 ( 1 ): 4 - 7,11 .
蔡嫣然 , 江丽杰 , 李子赟 , 等 . 痰瘀兼化:冠心病病机新论及临床应用 [J]. 中国中医基础医学杂志 , 2019 , 25 ( 1 ): 100 - 102,126 .
庞世德 , 吴华堂 . 加味黄连温胆汤联合西药治疗老年冠心病慢性稳定性心绞痛疗效及对血管内皮功能的影响 [J]. 中医药临床杂志 , 2020 , 32 ( 11 ): 2146 - 2149 .
王慧禹 , 焦晓民 . 小陷胸汤合温胆汤治疗冠心病心绞痛60例观察 [J]. 中医药临床杂志 , 2017 , 29 ( 2 ): 219 - 221 .
王阶 , 陈光 . 冠心病稳定型心绞痛中医诊疗专家共识 [J]. 中医杂志 , 2018 , 59 ( 5 ): 447 - 450 .
袁渊 , 蒲清荣 , 黄锐 , 等 . 丹参饮对冠脉结扎大鼠心肌缺血的保护研究 [J]. 现代药物与临床 , 2017 , 32 ( 12 ): 2299 - 2303 .
廖昔威 , 林辉 , 徐大量 , 等 . 丹参饮复方提取物-A对心肌缺血大鼠的保护作用研究 [J]. 中药材 , 2017 , 40 ( 8 ): 1944 - 1947 .
MU F , DUAN J , BIAN H , et al . Cardioprotective effects and mechanism of radix salviae miltiorrhizae and lignum dalbergiae odoriferae on rat myocardial ischemia/reperfusion injury [J]. Mol Med Rep , 2017 , 16 ( 2 ): 1759 - 1770 .
白宇明 , 黄莉 . 二陈汤合血府逐瘀汤治疗痰瘀互结型冠状动脉粥样硬化性心脏病心绞痛的临床效果 [J]. 中国医药 , 2019 , 14 ( 5 ): 659 - 663 .
0
浏览量
1
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号